CBD:CBDA Cannabinoid Composition for Severe Inflammation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for inflammatory conditions and autoimmune diseases do not work and can cause life-threatening responses, and existing therapies are not effective for severe cases.
Innovation Solution
Cannabinoid compositions, particularly a 1:1 equimolar mixture of CBD:CBDA, are used to reduce cytokine levels, induce autophagy, and exhibit antioxidant activity, formulated with pharmaceutical carriers for various administration routes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TNF inhibitors are used to treat severe inflammatory conditions or autoimmune diseases, then therapeutic efficacy is improved, but life-threatening responses and severe side effects occur
Solution Approach 1:
The patent extracts and isolates specific cannabinoid compounds (CBD, CBDA, and their equimolar mixture) from the Cannabis plant to create a targeted therapeutic agent. This extraction approach allows for precise control over the active ingredients, separating the beneficial anti-inflammatory effects from the harmful side effects associated with conventional TNF inhibitors.
Solution Approach 2:
The patent changes the chemical parameters by using specific cannabinoid compounds and their equimolar mixture, which have different pharmacological properties compared to TNF inhibitors. The equimolar ratio of CBD:CBDA (1:1 molar ratio) represents a specific parameter optimization that enhances therapeutic efficacy while reducing toxicity.
2Object-affected harmful factors
If conventional synthetic DMARDs and corticosteroids are used to treat inflammatory conditions, then anti-inflammatory effects are achieved, but treatment effectiveness is insufficient for severe cases
Solution Approach 1:
The patent employs a composite therapeutic approach by combining two different cannabinoid compounds (CBD and CBDA) in an equimolar mixture. This composite formulation leverages the synergistic effects of both compounds, where CBD provides immunosuppressant activity and CBDA contributes to anti-inflammatory effects, creating a more effective treatment for severe cases than either compound alone.
Data Source
AI summary
This disclosure describes compositions including cannabinoids and methods of using those compositions including, for example, to treat or prevent inflammation, as an immunosuppressant, and/or as an anti-cancer therapeutic. In some aspects, the pharmaceutical composition comprises an approximately 1:1 equimolar mixture of CBD:CBDA In other aspects, the pharmaceutical composition comprises a cannabinoid; and an approximately 1:1 equimolar mixture of CBD:CBDA. The cannabinoid may comprise at least one of CBC, CBCA, CBD, CBDA, CBDV, CBDVA, CBG, CBGA, CBL, CBLA, CBN, CBNA, THCV, or THCVA.